This is corroborated by evidence demonstrating that neutralization of IFN-γ using anti-IFN-γ mAb leads to reduced AT2 cell proliferation and attenuated AT2-to-AT1 cell differentiation after SpT4 infection, which are similar to the effects observed with anti-CD8 mAb treatment. Here, SUPT4H1 is linked to infection.